Decent, safe work
A (87)
Screens
Advertising
Alcohol
Anti-abortion support
Cannabis
Carbon emissions intensity
Coal
Deforestation - financing
Deforestation - supply chain
Discrimination controversies
Environmental controversies
Factory farming
Fast food
Firearms
For-profit health care
Fossil fuel
Fur
Gambling
Genetic engineering
Health-related controversies
Human rights controversies
Human trafficking
Interest-based products
Interest-bearing debt
Interest-bearing securities
Iran
Military contracting
Misleading communication
Music
Myanmar
Norges Bank exclusion list
Northern Ireland (Macbride)
North Korea
No SBTI commitment
Nuclear
Oil and gas
Opioid controversies
Oppressive governments
Pharma controveries
Pork
Pornography
Predatory lending
Prison involvement
Privacy breaches
Pro-life
Russia
Single-use plastic
Sudan
Sugar
Syria
Tobacco
Undermining US elections
Weapons
Impact

Cause BIIB
Peer rank
Decent, safe work

Name Rating
Loading...
Screens
Advertising
Alcohol
Anti-abortion support
Cannabis
Carbon emissions intensity
Coal
Deforestation - financing
Deforestation - supply chain
Discrimination controversies
Environmental controversies
Factory farming
Fast food
Firearms
For-profit health care
Fossil fuel
Fur
Gambling
Genetic engineering
Health-related controversies
Human rights controversies
Human trafficking
Interest-based products
Interest-bearing debt
Interest-bearing securities
Iran
Military contracting
Misleading communication
Music
Myanmar
Norges Bank exclusion list
Northern Ireland (Macbride)
North Korea
No SBTI commitment
Nuclear
Oil and gas
Opioid controversies
Oppressive governments
Pharma controveries
Pork
Pornography
Predatory lending
Prison involvement
Privacy breaches
Pro-life
Russia
Single-use plastic
Sudan
Sugar
Syria
Tobacco
Undermining US elections
Weapons
Top metrics
Sample of top metrics driving Biogen's rating for decent, safe work opportunities (A, relative to other companies). Hover or click on a bubble for more info. See details for all metrics in table below
Loading...
All metrics
Metrics used to rate Biogen for decent, safe work opportunities. Click on a metric for more info
Metric Source Data Normalized
Loading...

Data status

Summary statistics on data used to rate Biogen for decent, safe work opportunities

...

of potential metrics used

...

unique data

...

peer-average data

about 19 hours ago

last updated

...

company filings data

...

government data

...

Ethos research

...

independent organization data
Controversies
Controversies associated with Biogen. Click on a controversy for more info
Title Date Severity
Loading...
* Indicates data is an average of peer group, or industry if peer data not available. Used when data for company not available.
Normalized scores are relative to other companies. Learn more about our ratings methodology
Note that all controversies information is based on publicly-available information.
BIIB Price
$291.90
Last available end-of-day price. Full disclosure
Revenue
$10.36 billion
Market cap
$41.08 billion
Public/private
Public
Hypothetical historical growth of $10,000
Historical performance
Company
Founded
1978
Employees
9,610
Sector
Healthcare
Industry
Pharmaceuticals & Biotech
Peer group
Biotechnology
Headquarters
Massachusetts, United States
Share classes
BIIB
Mission
We are pioneers in neuroscience. Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases.
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Material causes
Ethos considers the following causes material for Biogen, based on its industry peer group Biotechnology. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.